With big pharma leaning on external pipelines, the company sees opportunity in de-risked, high-impact assets with clear clinical endpoints
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
The capital will be deployed to deepen AI-driven personalisation capabilities, expand its dark store network, and build a strong offline retail presence
Our company is prioritising deeper collaborations with CDMOs and biosimilar companies as part of its strategy to expand its footprint across India, Middle East, and Africa region
CLIRNET plans to expand globally and improve how medical knowledge is shared and used in practice
Shift from approvals to digital intimation via NSWS portal aims to cut timelines and boost innovation in early-stage drug development
Analysts expect modest revenue growth but pressure on profitability in the March quarter
At India Pharma 2026, Dr Bahl calls for experimentation over imitation as funding rises and translational ecosystem reforms gather pace
Outlines 1,500-member internal cadre, digital regulatory system, and faster SEC-led reviews
Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics
Subscribe To Our Newsletter & Stay Updated
